Astellas earmarks $354.2M for Irish build; Samsung Biologics get into ADCs; Rentschler gets UK facility approved

Wel­come to our new look for man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls, and more.

This week, we take a look at Sam­sung Bi­o­log­ics’ new deal with Ko­re­an biotech Aimed­Bio as well as Rentschler Phar­ma’s move in­to the UK. Al­so, we ze­ro in on the US gov­ern­ment’s fund­ing in­to NTx for RNA man­u­fac­tur­ing and South Ko­rea and Ser­bia’s new vac­cine man­u­fac­tur­ing deal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.